Ansilo Health is an integrated pharmaceutical company focused on commercialisation, manufacturing, quality systems, and pharmaceutical intelligence — serving patients, partners, and healthcare systems across Africa.
R10b
Enterprise Value Projected, Y10
100+
Years Combined Executive Experience
3
Integrated Divisions
4
Capability Areas
Market Context
Ansilo is being built at a convergence of structural trends that make this the right moment for a focused, Africa-based pharmaceutical company.
Africa has the world's fastest-growing population, with rising chronic disease burden and expanding healthcare demand creating a structural need for pharmaceutical capability.
Expanding insurance coverage, government health programmes, and healthcare infrastructure investment are growing the addressable market across the continent.
Post-COVID recognition of healthcare sovereignty has accelerated policy support for domestic pharmaceutical production and medicine security across African nations.
Global supply chain disruption exposed the risks of import dependency. Governments and multinationals alike are seeking diversified, locally based supply partners.
Global pharmaceutical companies are streamlining African portfolios, creating a pipeline of acquisition, licensing, and commercialisation opportunities for capable local operators.
South African and continental policy frameworks increasingly favour local production, medicine security, and healthcare system strengthening through industrial policy support.
Industry context:Industry estimates suggest Africa imports over 70% of pharmaceutical requirements. The continent's pharmaceutical market is growing, driven by demographic and policy trends. Multinational rationalisation is creating portfolio opportunities for capable local operators.
“Ansilo is positioned at the intersection of these trends — building an integrated pharmaceutical company for the African market.”
What We Do
Four integrated areas of pharmaceutical expertise — each representing a core capability that together form a comprehensive pharmaceutical operating platform.
Portfolio management, product licensing, and market access services with established commercial infrastructure for multinational partners.
Local manufacturing capability development, contract manufacturing partnerships, and generic medicines development for the African market.
Pharmaceutical quality testing, stability services, GMP-compliant operations, and regulatory dossier management for SAHPRA submissions.
Advanced analytics for portfolio optimisation, commercial forecasting, and data-driven operational decision-making across the pharmaceutical value chain.
Our Impact
Patient outcomes are our north star. Everything we build is designed to strengthen healthcare systems and improve access to quality medicines.
Working to improve access to quality, affordable medicines across African healthcare systems through local commercialisation and manufacturing capability.
Reducing Africa's dependence on imported medicines by building local pharmaceutical production and supply chain capability that strengthens healthcare sovereignty.
Building local pharmaceutical expertise through skills development, knowledge transfer, and the creation of high-quality pharmaceutical jobs across the continent.
“Healthcare is not a commodity — it is a fundamental human need. Building pharmaceutical capability in Africa is one of the most important contributions we can make to the continent's future.”
Dr Michael Klein
Founder, Ansilo Health
Why Ansilo
Five pillars that position Ansilo to execute on its mission of building an integrated pharmaceutical company for Africa.
Pharmaceutical executives with multinational experience and African market knowledge. Combined decades of regulatory, commercial, and operational expertise in pharmaceutical markets.
Anchor portfolio with established commercial revenue, diversified across therapeutic categories reducing single-product risk. Pipeline of identified acquisition targets from multinational rationalisation.
Commitment to GMP-compliant quality systems from day one. Regulatory expertise in SAHPRA submissions, dossier management, and pharmaceutical quality assurance.
Strategic relationships with multinational pharmaceutical companies. Institutional funding engagement demonstrating institutional validation. Professional advisor network supporting transaction execution.
Structured capital approach: founder equity, development finance, and strategic partner participation. Capital structure designed for institutional compatibility and long-term growth.
R10b
Enterprise Value Projected, Y10
100+
Years Combined Executive Experience
R200M
Primary Institutional Funding
Subject to due diligence and approvals
Founder's Vision
Ansilo exists to fill a critical gap between Africa's pharmaceutical needs and its current capability. The continent imports the majority of its medicine requirements — a structural vulnerability that affects patient access, healthcare quality, and economic development.
Building African pharmaceutical capability matters because healthcare sovereignty is essential for sustainable development. When medicines are produced locally, supply chains are more resilient, costs are more accessible, and health outcomes improve.
The long-term ambition is to build one of Africa's most important pharmaceutical companies — an institution that serves patients, creates value for partners, and demonstrates that world-class pharmaceutical capability can be built on the continent.
“Our goal is to build one of Africa's most important pharmaceutical companies — serving patients, creating value for partners and investors, and demonstrating that world-class pharmaceutical capability can be built on this continent.”
Dr Michael Klein
Founder
Executive Team
Experienced pharmaceutical executives with multinational track records, deep regulatory knowledge, and proven African market expertise.
Founder
Pharmaceutical strategy, corporate finance, and transaction execution. Leading Ansilo's vision of building an integrated pharmaceutical company for Africa.
General Manager
Pharmaceutical operations and country management with extensive P&L leadership experience in African pharmaceutical markets.
Chief Financial Officer
Financial strategy, DFI engagement, and corporate governance. Expertise in capital raising, financial reporting, and institutional investor relations.
Chief Commercial Officer
Commercial strategy, brand management, and pharmaceutical sales leadership with a track record of building successful commercial organisations.
Chief Regulatory Officer
SAHPRA submissions, regulatory compliance, and GMP auditing expertise. Deep experience in pharmaceutical regulatory affairs and quality systems.
Medical Director
Clinical governance, medical affairs, and healthcare professional engagement. Expertise in pharmaceutical medical management and patient safety.
Chief Supply Chain Officer
Pharmaceutical logistics, 3PL management, and supply chain operations. Expertise in building resilient pharmaceutical supply chains for African markets.
Operations Manager
Facility operations, production planning, and operational execution. Experience in pharmaceutical manufacturing operations and quality management.
Partnership Value
Six reasons pharmaceutical companies choose to work with Ansilo as their African partner.
Deep understanding of African pharmaceutical markets, regulatory environments, healthcare systems, and commercial dynamics across the continent.
Established sales, marketing, and distribution capability to bring products to patients across the region with professional commercial execution.
SAHPRA submission expertise, dossier management, and regulatory compliance capability built on decades of combined pharmaceutical regulatory experience.
GMP-compliant quality framework ensuring product integrity and patient safety, with quality culture embedded in our operating philosophy from day one.
Ability to structure partnerships across licensing, distribution, co-commercialisation, and portfolio transfer — tailored to each partner's strategic objectives.
Ansilo is built for the African market as a permanent institution, not a temporary entrant. Partners can rely on sustained presence, investment, and relationship continuity.
Capital & Strategy
Building an integrated pharmaceutical company for Africa — with a phased approach designed for institutional relevance and long-term value creation.
Acquire and manage established pharmaceutical portfolios, generating immediate cash flow and building commercial infrastructure for broader operations.
Build pharmaceutical quality testing and regulatory capability as a standalone service line, supporting both internal and external clients.
Develop local pharmaceutical manufacturing capacity, beginning with contract manufacturing and progressing to branded generics and specialty products.
R60B+
South African pharmaceutical market1
70%+
Import dependency across Africa2
8-10%
Estimated market CAGR3
1 Industry estimates. 2 According to industry research on African pharmaceutical import dependency. 3 Market data indicating estimated growth rate.
Engage With Us
Choose your pathway to engage with Ansilo Health. We work with pharmaceutical companies, investors, governments, and future team members.
Commercialisation infrastructure, regulatory capability, and African market access for multinational partners seeking reliable local representation.
Explore PartnershipsInstitutional structure, governance framework, development impact, and healthcare resilience investment opportunity with clear strategic rationale.
Investor InformationLocal manufacturing, medicine security, healthcare system strengthening, and regulatory compliance partnership for public health objectives.
Government PartnershipsMission-driven pharmaceutical careers with meaningful impact on African healthcare. Join a team building an institution for the continent.
Join Our TeamLatest Updates
Company announcements, thought leadership, and industry insights from the Ansilo team.
